JUL 0 2 200%

PTO/SB/26 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paper vert Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

ERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional) 0609.4110001/LBB/FRC

In re Application of:

TANZI et al.

Application No.;

09/425,956

Filed:

October 25, 1999

A Diagnostic Assay for Alzheimer's Disease: Assessment of AB Abnormalities

JUL 08 2004

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

Check either box 1 or 2 below, if appropriate.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. ___ The undersigned is an attorney or agent of record.

07/06/2004 SDIRETAI 00000144 09425956

03 FC:2814

55.00 OP

Frances Toneguzzo, Ph.D.
Typed or printed name

817- 726:1068


Telephone Number

 $\frac{\mathrm{X}}{\mathrm{I}}$ Terminal disclaimer fee under 37 CFR 1.20(d) included.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



P:\USERS\UKIM\0609\411\373.411 SKGF Rev. 1/95

Certificate Under 37 C.F.R. § 3.73(b)

Applica	ants: Rud	olph E. TANZI, Ashley	I. BUSH, and Robert	D. MOIR	VECH CENTER 1600/2966
Applica	ation No:_	08/817,423		International Filing Date: 9	October 19, 1994
For: <u>A</u>	<u>Diagnost</u>	<u>ic Assay for Alzheimer</u>	's Disease: Assessme	nt of Aβ Abnormalities	
The Ge	neral Hos	pital Corporation, a c	orporation (Type of	Assignee, e.g., corporation, partnership, univ.	ersity, government agency,etc.)
	s that it is of either:	the assignee of the entir	e right, title and intere	st in the patent application	identified above by
A. [X] [or]		d in the Patent and Trade		lication identified above. T	
B. []	A chain shown b		or(s) of the patent appl	ication identified above to t	he current assignee as
	1. From	: The document was reco	orded in the Patent and	Trademark Office at which a copy thereof is att	cached.
	2. From	:	orded in the Patent and	Trademark Office at which a copy thereof is att	ached.
	3. From	:	orded in the Patent and		ached.
	[]Add	itional documents in the	chain of title are listed	l on a supplemental sheet.	
[X] Co _l	pies of ass	signments or other docur	nents in the chain of ti	tle are attached.	
				f title of the patent application the assignee identified about	
The und	dersigned	(whose title is supplied	below) is empowered	to act on behalf of the assig	gnee.
informa that wil 1001, T	ation and l lful false itle 18 of	belief are believed to be statements, and the like	true; and further, that so made, are punishab and that such willful f	wledge are true, and that al these statements are made valle by fine or imprisonment, alse statements may jeopar	with the knowledge or both under Section
Date:		1/11/97	· · · · · · · · · · · · · · · · · · ·		
Name: ˌ		DAVID J. GLASS, Ph.D. SSOCIATE DIRECTOR FOR PATEI	•••		
Title:		OFFICE OF TECHNOLOGY AFFAIR	AS .		
Signatu	re:				

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

DO NOT FORWARD TO ASSIGNMENT BRANCH NOT FOR RECORDATION

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned: Rudolph E. TANZI, Ashley I. BUSH, and Robert D. MOIR, the undersigned hereby sell(s) and assign(s) to The General Hospital Corporation (the Assignee) his/her entire right, title and interest

check applicable box(es)

☐ for the United States of America (as defined in 35 U.S.C. § 100),
☐ and throughout the world,

in the invention(s) known as A Diagnostic Assay for Alzheimer's Disease: Assessment of Aß Abnormalities for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 6/21/67

7/11/67 6/24/67 (also known as United States Application No. 08/817,423, international filing date October 19, 1994), in any and all applications thereon, in any and all Letters Patent(s) therefor, and in any and all reissues, extensions, renewals, reexaminations of such applications or Letters Patent(s) and divisional and continuation applications thereof, to the full end of the term or terms for which such Letters Patent(s) issue, such entire right, title and interest to be held and enjoyed by the above-named Assignee to the same extent as they would have been held and enjoyed by the undersigned had this assignment and sale not been made.

The undersigned agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

The undersigned agree(s) to execute all papers necessary in connection with any interference that may be declared concerning the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference.

The undersigned hereby represents that the undersigned has full right to convey the entire interest herein assigned, and that the undersigned has not executed, and will not execute, any agreement in conflict therewith.

The undersigned hereby grant(s) Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michaele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; and Andrea G. Reister, Esquire, Registration No. 36,253, of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

	IN WITNESS WHEREOF, executed by the undersigned on the date(s) opposite their nam	ie(s).	
Date: χ_			
Date: ⊀	7/1/97 Signature of Inventor: X Rudolph E. TANZI		
7	Ashley I. BUSA	* -	
Date: <u>火</u>	Signature of Inventor: White May Robert D. MOIR		·

P:\USERSVKIM\0609\411\ASSIGN.411

#36,681